PLAINSBORO, N.J., Sept. 25, 2015 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for ...

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an expanded use for Tresiba (insulin degludec) injection to improve glycemic control in children and adolescents with ...

The Tresiba label was updated to reflect safety outcomes from the DEVOTE trial. Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an update to the prescribing information ...

Novo Nordisk has received European approval for two new diabetes products – Tresiba and Ryzodeg – that are central to its growth plans for the next few years. Tresiba (insulin degludec) and Ryzodeg ...

People with diabetes have been hit with a five-month shortage of a vital medication. The Tresiba FlexTouch U100 insulin pen, which is manufactured by global pharmaceutical giant Novo Nordisk, is ...

Novo Nordisk NVO announced that Tresiba and Ryzodeg 70/30 have gained the long-awaited FDA approval for the treatment of diabetes mellitus in adults. Novo Nordisk intends to launch Tresiba in the U.S.

Insulin degludec is available in FlexTouch ®, Novo Nordisk's latest prefilled insulin pen, and is offered in two concentrations enabling maximum doses of up to 80 and 160 units per single injection.

Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (:MHLW) approved ...